Needham analyst Michael Matson reiterated a Buy rating on Boston Scientific Corp (BSX) today and set a price target of $53.00. The company’s shares closed last Monday at $40.26.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 5.5% and a 59.6% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies Inc, Cardiovascular Systems, and Zimmer Biomet Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific Corp with a $48.69 average price target, a 19.5% upside from current levels. In a report issued on October 14, Raymond James also maintained a Buy rating on the stock with a $48.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $43.84 and a one-year low of $31.56. Currently, Boston Scientific Corp has an average volume of 6.29M.
Based on the recent corporate insider activity of 158 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.
